# TARA-002

Source: https://onco.cc/drugs/tara-002/  
OnCo record `tara-002` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TARA-002 is an experimental cell therapy whose type is not stated from Protara Therapeutics in phase 3 trials for bladder & urothelial cancer, with its target not yet stated publicly.

## Summary

TARA-002 is a cell therapy whose type is not stated developed by Protara Therapeutics. The sponsor describes its target as non-muscle invasive bladder cancer and lymphatic malformations, which OnCo does not yet have a target page for. The sponsor states: TARA-002 is based on OK-432, a broad immunopotentiator that is approved in Japan and Taiwan for other indications. ClinicalTrials.gov describes the intervention as: All participants will receive 6 weekly instillations of TARA-002 at the established RP2D (First Treatment Period). Participants who are eligible for reinduction after the First Treatment Period will receive 6 additional weekly doses of TARA. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT07480356 (Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer), in bladder & urothelial cancer. The largest, NCT07480356, plans to enrol 284 participants with primary completion expected 2028-04. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: cell therapy (type not stated)
- Mechanism: TARA-002 is based on OK-432, a broad immunopotentiator that is approved in Japan and Taiwan for other indications.

## Sources

- ClinicalTrials.gov: trials of TARA-002: https://clinicaltrials.gov/search?intr=TARA-002
- Sponsor page: https://www.protaratx.com/

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- companies: [Protara Therapeutics](https://onco.cc/companies/protara-therapeutics/)
- trials: [Efficacy and Safety of Intravesical TARA-002 Compared With Investigator's Choice of Intravesical Chemotherapy in Participants With BCG-naïve High-grade Non-muscle Invasive Bladder Cancer](https://onco.cc/trials/nct07480356/), [Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer](https://onco.cc/trials/nct05951179/)

---
JSON: https://onco.cc/api/v1/entities/tara-002.json